Compare SPRO & FRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRO | FRD |
|---|---|---|
| Founded | 2013 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Steel/Iron Ore |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.5M | 134.3M |
| IPO Year | 2017 | 1995 |
| Metric | SPRO | FRD |
|---|---|---|
| Price | $2.34 | $17.62 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 251.4K | 24.7K |
| Earning Date | 03-26-2026 | 02-09-2026 |
| Dividend Yield | N/A | ★ 0.89% |
| EPS Growth | ★ 111.81 | N/A |
| EPS | 0.15 | ★ 1.46 |
| Revenue | $66,802,000.00 | ★ $121,157,278.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $12.34 |
| Revenue Growth | 39.24 | ★ 55.82 |
| 52 Week Low | $0.51 | $12.24 |
| 52 Week High | $3.09 | $24.37 |
| Indicator | SPRO | FRD |
|---|---|---|
| Relative Strength Index (RSI) | 44.87 | 44.76 |
| Support Level | $2.31 | $16.26 |
| Resistance Level | $2.44 | $22.82 |
| Average True Range (ATR) | 0.12 | 0.90 |
| MACD | -0.02 | 0.11 |
| Stochastic Oscillator | 11.90 | 51.49 |
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.